Mazor Robotics to be included in TASE Top 75 Index and Top 100 Index from Dec 15, 2013

Mazor Robotics Ltd. (TASE: MZOR) (NASDAQCM: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that it will be included in both the Tel Aviv Stock Exchange (TASE) Top 75 Index (TA-75) and Top 100 Index (TA-100), effective December 15, 2013.

"We are very pleased to be included in these prestigious indices, which includes leading companies based in Israel," said Ori Hadomi, Chief Executive Officer. "This achievement reflects our performance in 2013 and confidence in our long term growth prospects. Furthermore, I believe this will increase our exposure among investors and will serve to broaden our shareholder base."

The TA-75 is a share index of the 75 most highly capitalized companies listed on the TASE, which are not included in the TA-25 index. The TA-100 Index, typically referred to as the Tel Aviv 100, is a stock market index of the 100 most highly capitalized companies listed on the TASE. The TASE is the only public market for trading securities in Israel, playing a major role in the Israeli economy. TASE lists some 622 companies, about 60 of which are also listed on stock exchanges in other countries. TASE also lists some 180 exchange-traded funds (ETFs), 60 government bonds, 500 corporate bonds, and more than 1,000 mutual funds.

Source: Mazor Robotics 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.